Harbor Investment Advisory LLC Sells 187 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Harbor Investment Advisory LLC lessened its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 23.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 615 shares of the medical instruments supplier’s stock after selling 187 shares during the period. Harbor Investment Advisory LLC’s holdings in LeMaitre Vascular were worth $57,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NBC Securities Inc. lifted its holdings in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the period. USA Financial Formulas bought a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $60,000. GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares during the period. Canada Pension Plan Investment Board acquired a new position in LeMaitre Vascular during the 2nd quarter worth approximately $82,000. Finally, Advisors Asset Management Inc. increased its position in LeMaitre Vascular by 180.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 1,191 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

Insider Transactions at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $98.00 on Thursday. LeMaitre Vascular, Inc. has a 52-week low of $56.04 and a 52-week high of $109.58. The firm has a 50 day moving average price of $98.28 and a two-hundred day moving average price of $92.19. The stock has a market cap of $2.20 billion, a P/E ratio of 53.55, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same period in the prior year, the company posted $0.33 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 15.6% compared to the same quarter last year. Analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on LMAT shares. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Oppenheimer reiterated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.